SPL-108 is under clinical development by Splash Pharmaceuticals and currently in Phase II for Ovarian Cancer. According to GlobalData, Phase II drugs for Ovarian Cancer have a 26% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how SPL-108’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
SPL-108 overview
SPL-108 is under development for the treatment of epithelial ovarian cancer, triple negative breast cancer, endometrial cancer, prostate cancer, liver cancer, brain cancer, age-related macular degeneration and rheumatoid arthritis. The drug candidate is administered through subcutaneous route. It acts by targeting CD44. The drug candidate as a monotherapy is also under development for the treatment of ovarian cancer.
Splash Pharmaceuticals overview
Splash Pharmaceuticals, Inc., is a clinical stage oncology company developing and advancing novel cancer therapies. The company is headquartered in United States.
For a complete picture of SPL-108’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
